As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the Cambridge-based company has matured into a biopharmaceutical titan with a market capitalization exceeding $50 billion. Today, Alnylam is no longer just a "biotech story"; [...]
MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its lead drug candidate, sonelokimab. The Swiss biotech company announced on January 8, 2026, that a successful Type B meeting with the U.
In a move that signals the end of an era for independent mRNA pioneers, BioNTech SE (Nasdaq: BNTX) has officially completed its acquisition of longtime rival CureVac N.V. (Nasdaq: CVAC). The finalization of the deal on January 6, 2026, marks the conclusion of a complex multi-stage merger that saw
As of January 8, 2026, the global financial landscape is undergoing a seismic shift driven by President Trump’s latest round of "tariff salvos." These aggressive trade policies, which dominated the legislative and executive agenda throughout 2025, have reached a critical juncture. While the administration frames these duties as essential
The biotechnology sector, long frozen in a capital-starved "biology winter," is showing definitive signs of a seasonal shift. On January 7, 2026, the industry witnessed a significant injection of capital as two prominent players, Monte Rosa Therapeutics (NASDAQ: GLUE) and Genelux Corporation (NASDAQ: GNLX), launched public offerings. These moves signal
Monte Rosa Therapeutics reported positive interim Phase 1 data for MRT-8102, showing significant anti-inflammatory effects in patients with elevated cardiovascular risk.
Move comes in response to a presidential memorandum issued by President Donald Trump in December, aimed at aligning U.S. vaccination practices with other developed nations.
In a move that has fundamentally reshaped the landscape of the pharmaceutical industry, Isomorphic Labs—the London-based drug discovery arm of Alphabet Inc. (NASDAQ: GOOGL)—has solidified its position at the forefront of the AI revolution. Through landmark strategic partnerships with Eli Lilly and Company (NYSE: LLY) and Novartis (NYSE: NVS) valued at nearly $3 billion, the [...]
The landscape of biological science underwent a seismic shift in November 2024, when Google DeepMind, a subsidiary of Alphabet Inc. (NASDAQ: GOOGL), officially released the source code and model weights for AlphaFold 3. This decision was more than a mere software update; it was a high-stakes pivot that ended months of intense scientific debate and [...]
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the industry has closed the year with a powerful rally, fueled by a dovish shift from the Federal Reserve and
The year 2025 has cemented a historic shift in the biological sciences, marking the end of the "guess-and-test" era of drug discovery. At the heart of this revolution is AlphaFold 3, the latest AI model from Google DeepMind and its commercial sibling, Isomorphic Labs—both subsidiaries of Alphabet Inc (NASDAQ:GOOGL). While its predecessor, AlphaFold 2, solved [...]
As of late 2025, the landscape of biological research has undergone a transformation comparable to the digital revolution of the late 20th century. At the center of this shift is AlphaFold 3, the latest iteration of the Nobel Prize-winning artificial intelligence system from Google DeepMind, a subsidiary of Alphabet Inc. (NASDAQ: GOOGL). While its predecessor, [...]
In a milestone that cements artificial intelligence as the most potent tool in modern science, Google DeepMind’s AlphaFold has officially surpassed 3 million users worldwide. This achievement coincides with the five-year anniversary of AlphaFold 2’s historic victory at the CASP14 competition in late 2020—an event widely regarded as the "ImageNet moment" for biology. Over the [...]
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme binary outcomes, the market saw one of the most significant single-day collapses in recent history alongside a
Novartis (NVS) presents a classic value investing case: a financially strong pharmaceutical leader trading at a discount to peers, with high profitability and a solid dividend.
In the final weeks of 2025, the scientific community is reflecting on a year where the boundary between computer science and biology effectively vanished. The catalyst for this transformation was AlphaFold 3, the revolutionary AI model unveiled by Google DeepMind and its commercial sibling, Isomorphic Labs. While its predecessor, AlphaFold 2, solved the 50-year-old "protein [...]
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts by surprise. After years of trading in the shadow of high interest rates and regulatory uncertainty, the industry
